Medical imaging company Arterys Inc revealed on Thursday the receipt of its fifth 510(k) clearance from the US Food and Drug Administration (FDA) for the Arterys Oncology AI suite for the evaluation of primary and metastatic disease in the lung and liver initially.

This US FDA's milestone clearance is indicative of the company's momentum in applying AI to advance medical imaging accuracy and consistency. It now expands its clinical offerings with two new AI-powered workflows for medical imaging interpretation of the lung and liver.

According to the company, its Oncology AI runs on the Arterys MICA (Medical Imaging Cloud AI) platform, which is easier to deploy than on-premise imaging systems and complies with patient data privacy and security requirements in 27 countries, including the US, Canada, all of Europe, Australia,and New Zealand.

The company said the Oncology AI software uses deep learning to automate the segmentation of lung nodules and liver lesions, with accuracy equal to segmentations performed manually by experienced clinicians. The clinician has the capability to edit these automated segmentations and remain in control.

With this new technology, the radiologists can now easily confirm, evaluate, quantify and report on the absence or presence of lung nodules and liver lesions along with their key characteristics using a simple web browser, concluded the company.